Hookipa Pharma (HOOK) Stock Price, News & Analysis

Company Overview

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Key Stats

• Today's Range: $2.58 to $2.75
• 50-Day Range: $2.72 to $5.10
• 52-Week Range: $2.58 to $11.30
• Volume: 16,013 shs
• Average Volume: 57,217 shs
• Market Capitalization: $31.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $38.33
• Consensus Rating: Buy

Hookipa Pharma Stock Analysis - MarketRank™

Hookipa Pharma scored higher than 49% of companies evaluated by MarketBeat, and ranked 611th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Hookipa Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Hookipa Pharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Hookipa Pharma is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hookipa Pharma is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hookipa Pharma has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.47% of the float of Hookipa Pharma has been sold short.

Short Interest Ratio / Days to Cover

Hookipa Pharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hookipa Pharma has recently increased by 39.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hookipa Pharma does not currently pay a dividend.

Dividend Growth

Hookipa Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.47% of the float of Hookipa Pharma has been sold short.

Short Interest Ratio / Days to Cover

Hookipa Pharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hookipa Pharma has recently increased by 39.23%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.19

News Sentiment

Hookipa Pharma has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Hookipa Pharma this week, compared to 1 article on an average week.

Search Interest

3 people have searched for HOOK on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hookipa Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.30% of the stock of Hookipa Pharma is held by insiders.

Percentage Held by Institutions

63.88% of the stock of Hookipa Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HOOK Stock Analysis - Frequently Asked Questions

How have HOOK shares performed this year?

Hookipa Pharma's stock was trading at $8.10 at the start of the year. Since then, HOOK stock has decreased by 66.4% and is now trading at $2.72.
View the best growth stocks for 2024 here.

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.44) by $0.08. The business had revenue of $1.29 million for the quarter, compared to analyst estimates of $5.68 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 33.31% and a negative net margin of 86.74%.

When did Hookipa Pharma's stock split?

Shares of Hookipa Pharma reverse split on Wednesday, July 10th 2024. The 1-10 reverse split was announced on Wednesday, July 10th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Hookipa Pharma IPO?

Hookipa Pharma (HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

Who are Hookipa Pharma's major shareholders?

Top institutional shareholders of Hookipa Pharma include Baker BROS. Advisors LP (6.74%), Knoll Capital Management LLC (4.58%), FMR LLC (2.83%) and Redmile Group LLC (0.88%). Insiders that own company stock include Jorn Aldag and Reinhard Kandera.
View institutional ownership trends.

How do I buy shares of Hookipa Pharma?

Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Hookipa Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hookipa Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Pfizer (PFE), Advanced Micro Devices (AMD), Cabaletta Bio (CABA) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:HOOK
• CUSIP: N/A
• CIK: 1760542
• Web: www.hookipapharma.com
• Phone: 431-890-6360
• Fax: 43-1890-636-0399
• Employees: 56
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $44.00
• High Stock Price Target: $60.00
• Low Stock Price Target: $24.00
• Potential Upside/Downside: +1,517.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-81,580,000.00
• Net Margins: -86.74%
• Pretax Margin: -86.42%
• Return on Equity: -33.31%
• Return on Assets: -21.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.26
• Quick Ratio: 3.26

Sales & Book Value

• Annual Sales: $20.13 million
• Price / Sales: 1.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.08 per share
• Price / Book: 0.30

Miscellaneous

• Outstanding Shares: 12,060,000
• Free Float: 11,657,000
• Market Cap: $32.80 million
• Optionable: Optionable
• Beta: 0.84